While type II JAK2 inhibitors are not currently in clinical development, other strategies aimed at complete inhibition of JAK2 (such as HSP90 inhibitors) may produce greater anti-leukemia efficacy than ruxolitinib in CRLF2-re Ph-like ALL [35, 36]. The gene discussed is CRLF2; the disease is leukemia.